Vir Biotechnology lands a license agreement with Japan’s Astellas Pharma for its lead drug candidate.

Advanced Micro Devices rallies after the chip maker unveils a multi-year deal to supply computing power to Meta Platforms, ...

Biotech hot picks spotlight Xenon, United Therapeutics and Axsome as Phase III data and FDA decisions approach.

Vir Biotechnology (VIR) is experiencing a surge of +58% pre-market due to a significant strategic partnership with Astellas concerning its prostate cancer ...

This player's pipeline should keep growth going over the long run.

If you're looking for a stock that may skyrocket, it's often important to start small. By this, I mean uncovering names that ...

Apogee Therapeutics (NASDAQ: APGE) is one of the 17 biotechnology stocks with more than 50% upside. On January 25, Citi analyst Geoff Meacham maintained a Buy rating on Apogee Therapeutics ...

Grail (GRAL) stock is plummeting after the company's three-year cancer screening trial failed to meet its main goal ...

AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI ...

Centessa Pharmaceuticals develops clinical-stage therapies for rare and serious diseases, leveraging a portfolio approach in ...

Journey Medical dermatology revenue plus Emrosi near-term sales and a rare pediatric disease PRV from Zycubo approval. See ...

A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension (PAH) has missed its primary endpoint, triggering a 77% crash in the biotech’s share price. The company has paused ...